Will Circulating Tumor DNA Help Predict HPV-Related Throat Cancer?

A Keck Medicine of USC head and neck surgeon discusses circulating HPV DNA as a biomarker that could help make more individualized treatment decisions.

March 24, 2026
5 min

Keck Medicine of USC

Objective:

To explore the potential of circulating HPV DNA (HPV ctDNA) as a biomarker for predicting and monitoring HPV-related throat cancer.

Approach:

Key Findings:

Circulating HPV DNA levels correlate with disease burden in the body.
HPV ctDNA testing may provide real-time insights into treatment effectiveness.
Early detection of HPV ctDNA can inform additional treatment options.

Interpretation:

HPV ctDNA has the potential to revolutionize monitoring and treatment customization for HPV-related throat cancer, moving towards more individualized patient care.

Limitations:

Further research is needed to validate HPV ctDNA as a reliable biomarker.
Current assays for quantifying HPV DNA require scientific validation.

Conclusion:

HPV ctDNA testing could enhance treatment decision-making and patient involvement, but more studies are necessary to establish standardized protocols.